While Ozempic also bestowed 47% relative risk reduction to women, other GLP-1 receptor agonists slightly outperformed Ozempic in men (14% relative Alzheimer's disease risk).
While Ozempic also bestowed 47% relative risk reduction to women, other GLP-1 receptor agonists slightly outperformed Ozempic in men (14% relative Alzheimer's disease risk).